Navigation Links
Watson Receives FTC Clearance for Arrow Acquisition
Date:12/2/2009

MORRISTOWN, N.J., Dec. 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the Federal Trade Commission (FTC) has accepted a proposed consent order for public comment relating to Watson's pending acquisition of privately held Arrow Group and has granted early termination of the Hart Scott Rodino waiting period, thereby permitting the parties to close the transaction. The parties have now obtained all regulatory approvals required to close the transaction. Accordingly, the parties expect to consummate the acquisition of Arrow by Watson today.

Under the terms of a consent order with the FTC, Watson and Arrow have agreed to the following conditions to complete the transaction:

  • Watson will sell to Impax Laboratories, Inc. its Abbreviated New Drug Application (ANDA) for Cabergoline, the generic equivalent to Dostinex®.
  • Cobalt Pharmaceuticals, Inc. will sell to Impax Laboratories, Inc. its pending ANDA for Dronabinol, a generic equivalent to Marinol®.
  • Resolution Chemicals Ltd. (Resolution), the subsidiary of the Arrow Group that manufactures Dronabinol active pharmaceutical ingredient, and that will supply finished Dronabinol product to Impax Laboratories upon approval, will be sold to existing management of Resolution Holdings and divested from the Arrow Group immediately prior to the closing. Resolution has entered into an agreement with Impax Laboratories to supply finished Dronabinol product.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, successful integration of strategic transactions including the acquisition of the Arrow Group; the ability to recognize the anticipated synergies and benefits of strategic transactions, including the acquisition of the Arrow Group; the uncertainty associated with the successful consummation of external business development transactions, including the acquisition of the Arrow Group; the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Quarterly Report on Form 10-Q for the period ended September 30, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)

SOURCE Watson Pharmaceuticals, Inc.


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Completes Acquisition of Arrow Group
2. Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds
3. Watson Names G. Frederick Wilkinson Executive Vice President, Global Brands
4. Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B(R) for Over-the-Counter Use
5. Watson Prices $850 Million of Senior Unsecured Notes
6. Watson Announces Limited Recall Of Fentanyl Transdermal System
7. Watson Pharmaceuticals and Arrow Group Receive FTC Second Request
8. Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL(R) 25 MG and 50 MG
9. Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook
10. Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit(R)
11. Watson CFO Mark W. Durand to Take Leave of Absence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... A local study examining ... than 40 percent of participating fifth-grade students already have or are at risk ... Clinical Research in the Division of Pulmonary, Allergy and Critical Care Medicine at ...
(Date:5/5/2016)... NEW YORK (PRWEB) , ... May 05, 2016 , ... ... and swimming safety – today announced a new partnership to reach nearly 1 million ... can happen in an instant and is the leading cause of accidental death in ...
(Date:5/5/2016)... ... May 05, 2016 , ... Sun ... talk highlighting the organization’s successful Care Transitions program at the 9th ... was titled “Minimizing Costs in the Post-Acute Environment Through Effective Transitions of Care.” ...
(Date:5/5/2016)... ... , ... The 2016 Nike Soccer Camp will be directed by the 2015 ... Together they bring their winning Vandals coaching philosophy to young athletes. Programs are offered ... high school players. Session dates are as follows: , Youth Day Camp – July ...
(Date:5/5/2016)... ... May 05, 2016 , ... Talent Tech Labs (TTL) is pleased ... of National Nurses Week (May 6-12). Currently, HireNurses is a job listing ... into the Talent Tech Lab Virtual Incubation program, they will dramatically expand the functionality ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... WASHINGTON D.C. , May 4, 2016 /PRNewswire/ ... its member companies concluded a series of free ... training in global requirements for Good ... part of quality assurance which ensures that products are ... by the marketing authorization (MA) or product specification. Only ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute Ischemic Stroke Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Ischemic Stroke Market and Competitive Landscape Highlights ... Stroke pipeline products, Acute Ischemic Stroke epidemiology, ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute lymphocytic Leukemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Leukemia Market and Competitive Landscape Highlights 2016, ... pipeline products, Acute Lymphocytic Leukemia epidemiology, Acute ...
Breaking Medicine Technology: